Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would think as for enforcing the rules, regulatory bodies like Nasdaq play a crucial role in monitoring compliance with listing requirements and ensuring transparency in SPAC transactions. They oversee financial reporting, disclosure, and adherence to market regulations. Ultimately, it’s the responsibility of these authorities to ensure that SPACs follow the rules and maintain investor confidence.
Hopefully NASDAQ is looking into it along with the Judge. Maybe BM can write to NASDAQ
How long until we hear they have isolated the sites and will be in trials soon ..
https://www.nature.com/articles/s41467-023-43126-0
A/I answer below
Certainly! Monoclonal antibodies have emerged as a promising avenue for addressing the opioid crisis, particularly in the context of fentanyl. Here’s what we know:
Broadly Neutralizing Antibodies: Scientists at Scripps Research developed experimental antibodies that can block the lethal effects of synthetic opioids, including fentanyl and its potent cousin, carfentanil. These antibodies are referred to as “broadly neutralizing antibodies”. Unlike naloxone, which is commonly used to reverse opioid-related overdoses, these antibodies have a significantly longer half-life, remaining active in the body for more than a week. This extended duration is crucial because carfentanil persists in the body, and renarcotization can occur after an initial dose of naloxone. The Scripps Research antibodies offer a potential route for treating synthetic opioid overdose, either in combination with naloxone or as a stand-alone treatment. Additionally, there are potential applications in national defense, especially given carfentanil’s classification as a chemical terrorist threat1.
How Monoclonal Antibodies Work: Unlike current treatments that displace opioid molecules from receptors in the brain during an ongoing overdose, monoclonal antibodies bind to fentanyl molecules in the bloodstream before they can even reach the brain. This preventive approach could be a game-changer in tackling fentanyl-related deaths2.
FDA Approval for Testing: The Food and Drug Administration (FDA) has granted approval to a North Carolina biotech company to test whether a monoclonal antibody can prevent fentanyl overdoses. This development is critical because fentanyl is becoming a leading cause of death for people under 50. The antibody treatment doesn’t enter the brain, which also limits the risk of addiction3.
Florida’s Deadliest Drug: In Florida, where fentanyl is particularly prevalent, researchers are exploring an antibody treatment that recognizes and binds specifically to fentanyl and its analog molecules. Administered preemptively, this treatment aims to prevent overdoses by intercepting fentanyl in the bloodstream before it reaches the brain4.
In summary, monoclonal antibodies represent a novel and potentially life-saving approach to combat the devastating impact of fentanyl and other synthetic opioids. Their ability to neutralize these dangerous substances could make a significant difference in overdose prevention and treatment.
Learn more:
1. scripps.edu
2. usatoday.com
3. axios.com
4. axios.com
I dont know how you missed everything that was posted about the letter that was posted unsigned. Many of us posted the case , the judge ruling ect..It was a two day topic But whatever .
You were the one that brought up that you were 30 miles away , as for going to a location such as an university to just see if and what is going on I would say is pretty useful and safe again whatever.
Have a great weekend, we will still do the DD for you as usual. GLTA
Good news not us but is good for the ones that it can help. Costly but what isn't
https://www.msn.com/en-us/health/other/fda-approves-gene-therapy-for-sickle-cell-disease-one-incredible-journey-of-success/ar-AA1ld9wT?ocid=hpmsn&cvid=74d683483660486c8d9b58154a40a5db&ei=16
This is interesting look at the dates of the MC and when it was increased , is this just a filing delay. If deal was completed in Sept and shares issued to Enzolytics wouldn't the MC would have changed earlier in Oct 2023
https://ycharts.com/companies/SAGA/market_cap
You made that short drive yet?
Maybe this will help . HAHAHAHA
$ENZC The purpose of the Twitter Space tomorrow (@6pm) is to cover many of the catalysts in detail that are driving the monumental shift for Enzolytics.
— 𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 (@GodfatherCap) May 22, 2023
If the $250MM #SPAC deal and pending #dividend isn't enough to convince you, the other milestones will.
Winning 2023 🏆 https://t.co/KYl507le0K pic.twitter.com/xgyMI6sNpU
https://courts.delaware.gov/Opinions/Download.aspx?id=345220
Global web icon
Delaware Courts
https://courts.delaware.gov/Opinions/Download.aspx?id=345220
[PDF]IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
WebMar 16, 2023 · IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE. ENZOLYTICS, INC., Plaintiff, v. EMPIRE STOCK TRANSFER INC., and DIMITAR SAVOV, Defendants. ) ) ) ) …
Then you have this
https://twitter.com/ImKingofPrussia/status/1659634737743274002/photo/1
Remember all the cheerleaders were all stating Enzolytics will own a NASDAQ company , funny by the filings of SAGA the deal is completed and Enzolytics has owned 90% of SAGA for 2 months now and all Enzolytics has done is dropped in price. Where are they to explain this one to us?
What also is interesting , If you just got 2.3M+ shares of a company you are relying on for your company to exist under their Trading symbol would you step up and deposit the 171k into the holding account since you know they need to extend the SPAC in order to raise the funding you have stated you need to get things into trials?
Have a great night , we will just have to wait as usual to see the next twist that is coming.GLTA
Kinda like that old show Same Bat channel Same Bat time
Just pointing out one comapny increases in MC by adding 450m of shares , with no funding to support the value of said company yet another company adds an asset value at 450m and nothing. Just for a laugh lets say one owns a stock and that company you own stock in gets a winfall of shares of another company. Does your company value go up since it owns an asset greater than your companies worth or does it go down because you own something worth more than your company on paper. I remember people talking about the 450M should have increase our SP to around .10+ . All is good . Hopefully we get an answer to all of this soon.
I agree with you , just pointing out how 450M increases one company with nothing to show for it but for another it doesnt increase one bit. All is good we are on the same page January can't get here fast enough GLTA
Sorry but if one company has a MC of 553m , and another company holds 90% of the stock of that company , it should add value not decrease it. The shares have been issued to Enzolytics not a single shareholder has gotten anything so that means they are in Enzolytics assets holdings according to their posting of the deal. Yes or No?
So I guess noone can answer how SAGA on paper is showing a MC of 553m today , but the imaginary holdings of SAGA by ENZC hasn't increased the value instead it has decreased. SAGA can't pay roughly 171K into account that is required by their own SPAC guidelines where is the 110m from the original IPO they did? Did they submit their plan on time to SEC, NASDAQ ?
Hopefully this is all brought up to the judge and he rules that this complete SPAC gets shut down. Hopefully SEC looks into everything that has happened over the last two months.GLTA
I agree and shows why they couldnt complete a single deal over the past 2 years. It will be very interesting if the deal is shotdown how Enzolytics will explain the whole getting shares stating the deal was complete ect..
So that in itself shows they broke the terms of the SPAC. Thanks again for the post from earlier
So if what you are stating then ENZC currently should be valued 360m + in MC than it currently is since they hold 36m shares @11+ in their name not the shareholders correct? Why doesnt the MC show that for ENZC?
Thanks for the post .. Question this is copied from your post below. So if I read it correctly the fee for AUG was paid in OCT which would have been late, also that is after the deal was suppost to have been completed correct?
Attached hereto as Exhibit A are records of the payment made by SAGA for the August 23,
2023 extension fee (which was made on October 2, 2023)
Like I have said we don't know anything yet , it is a sit and wait for the judge to make a ruling , then we go from there at that point. Thanks for a new list that is atleast current.
They look like a better run SPAC than the one we have involved. GLTA
That is from 2021 , did you look at what each is trading at . 1 @ 50+ with a 1/10 stock split and a merger , 1 @ 9+ rest under a dollar .
SPAC was the thing then , they have fallen out of favor ,
Because of their high risk and poor historical returns, SPACs probably aren’t a suitable investment for most individual investors. But given attention seen in 2020 and 2021, and the increase in successful SPAC IPOs, the tide may change. If you decide to invest in SPACs, proceed cautiously and do thorough research ahead of time.
Investing in SPACs: Is It Worth It? - The Balance
www.thebalancemoney.com/investing-in-spacs-is-it-worth-it-5114999
www.thebalancemoney.com/investing-in-spacs-is-it-worth-it-5114999
Investing in Special Purpose Acquisition Companies (SPACs) has both pros and cons, and whether they are a good investment can depend on various factors.
Pros:
Speed and Efficiency: SPACs can offer speed and efficiency in the acquisition process1.
Diversification Opportunities: They provide diversification opportunities1.
Increased Liquidity: As they trade on public markets, they offer increased liquidity1.
Cons:
Trust in Promoters: An investor in a SPAC IPO trusts that promoters are successful in acquiring or merging with a suitable target company in the future2.
Reduced Oversight: There exists a reduced degree of oversight from regulators and a lack of disclosure from the SPAC2.
Risk of Overhype or Fraud: This burdens retail investors with the risk that the investment may be overhyped or even fraudulent2.
Cost: The cost of a SPAC IPO can be expensive3.
It’s important to note that investing always involves risks, and past performance does not guarantee future performance4. Therefore, it’s recommended to do thorough research and consider seeking advice from a financial advisor before making any investment decisions. Please remember that all investments carry some level of risk, including the potential loss of principal invested4.
Learn more:
1. supermoney.com
2. investopedia.com
3. schroders.com
4. russellinvestments.com
5. informaconnect.com
+2 more
Just want you to look at the date of this from Enzolytics this is gone full circle . This is what we are saying about the current news they are putting out.
https://finance.yahoo.com/news/enzolytics-reports-progress-toward-completion-113000008.html
https://finance.yahoo.com/news/correction-enzolytics-inc-reports-progress-190000692.html
https://www.accesswire.com/781111/patient-population-for-the-clinical-trials-of-itv-1-has-been-established-by-the-european-medicines-agency-ema
Enzolytics, Inc. is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. The company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system. Enzolytics, Inc. has provided an update regarding Virogentics, Inc.'s ITV-1 African Project. The final protocol for the administration of the ITV-1 immunotherapy treatment under the supervision of Neuro Pharma Ltd - Rwanda, to be dispensed to volunteers under a fast-track protocol at HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC, has been completed and delivered to the DRC Ministry of Health Department of HIV and Aids for final approval. The vials with the necessary informational inserts are awaiting the approval of the final protocol report for distribution. The impact of the treatment on the HIV/AIDS virus present in the volunteers will be reported after the 17-week cycle is complete. The African clinical trial is expected to conclude with a final report by the end of 202412.
Learn more:
1. finance.yahoo.com
2. biospace.com
3. enzolytics.com
4. bignewsnetwork.com
5. accesswire.com
6. enzolytics.com
7. enzolytics.com
+5 more
It has been an ongoing issue for years , it just didnt happen as you implied was the reason that ENZC could not start the trials. Congrads you won an award today , hopefully many will award you too.
Do some DD on war in Africa , and then compare the areas that ENZC wanted to be in.
Also explain that ENZC was in EU trials two years ago , where are they at now and results
https://reliefweb.int/report/world/conflict-trends-africa-1989-2021
GENIUS
Licensing ( Remember back when CC came aboard and stated that they are building a portfolio to license ) The trust holds the base work that was started by Harry dad . Currently Enzolytics has the exclusive rights that controls who can use it , I believe Harry will keep that in the trust run then thru Enzolytics and then the two subs with funding will expland on that. When they develop it further , or find new items to patent they will under the sub companies as they appear to be now.
Have you made the trip yet?
What has your buddy GF said about the whole deal and the dates that have been brought into questions now, meaning before you ask ( did they file on time to keep SPAC going, how did they issues shares ect. Why does the characters involve along with the deal look alittle shady . )
Bing or anyother A/I driven platform
Question who will be the ceo of enzolytics after the two subs are sold ?
Charles Cotropia is currently the CEO of Enzolytics12. After the sale of the two subsidiaries, Biogenysis, Inc. (“BGEN”) and Virogentics Inc. (“VIRO”), to Sagaliam Acquisition Corp, Dr. Gaurav Chandra has been appointed the Chief Executive Officer and Chairman of Biogenysis2. Charles Cotropia will continue as the Executive Director of Biogenysis and guide a comprehensive Intellectual Property strategy2. Please note that this information is accurate as of the last update and for the most current information, it’s best to check the official announcements from the company.
By this it seems CC time will be the deal complaiance and deal maker as Executive Director of Biogenysis and guide a comprehensive Intellectual Property strategy. So how will run Enzolytics or will he have dual duty when things are run thru Enzc from the trust and basiclly will be a copy paste until the drugs start proving to work or not. Should they work they will then adjust numbers to pay each company from production fees, then trial fees , and then the big move passing EMA and FDA . higher paids fees for better results until it is a widely used med at which point we hopefully will see money from 2 sources AKA subs for licensing imo GLTA
Learn more
1
finance.yahoo.com
2
nasda
Now same question with the other sub
Did Virogentics Inc file for patents in their name of the following listed as the company The Company has proprietary technology for producing fully human Monoclonal Antibodies (mAbs) against infectious diseases which is currently being employed to produ
Yes, Virogentics Inc. has filed for patents. The company has proprietary technology for producing fully human Monoclonal Antibodies (mAbs) against infectious diseases. One of their patented and clinically tested compounds is ITV-1 (Immune Therapeutic Vaccine-1), which is a suspension of Inactivated Pepsin Fraction (IPF). This compound is covered by U.S. Patent Nos. 8,066,982 and 7,479,538123. The IPF Technology has been shown to have broad-spectrum antiviral activity, targeting several viruses including influenza, HIV, and herpes simplex virus4. The company is constantly working to improve their IPF Technology and develop new treatments and preventions for viral infections4.
Learn more
1
accesswire.com
2
investorsobserver.com
Try doing the search with the question I presented and then switch the names out. That is the best I can tell you see what you get as the answer to the question. All that copy paste was the exact response I got from asking the same question with two name change. Again you really have to look at what each responds is saying and covering and not. If I wasnt looking at the two names I would say it was being run by the Binden's shells HAHAHA
It appears that ENZC filed certain patents then the sub filed patents on what their research discovered. So again I am thinking it will come down to what is held in the trust goes thru ENZC and then the subs will be granted the exclusive rights to build from there and it appears that is what the good doc is doing and they will do the heavy lifting from here if they get the funding. IMO again without seeing the details we are all throwing against the wall and seeing what sticks. GLTA
Let's look at this a different way , Can you show what Enzolytics will actually own ?
enzolytics is selling two subsidiaries what will enzolytics own after this deal is complete
Searching for: Enzolytics subsidiaries deal
Generating answers for you…
Enzolytics, Inc. has executed a binding business combination agreement for the sale of its operating subsidiaries, Biogenysis, Inc. (“BGEN”) and Virogentics Inc. (“VIRO”), to Sagaliam Acquisition Corp (NASDAQ: SAGA) in a transaction valued at $450,000,0001. After this deal, Enzolytics will no longer own these two subsidiaries. However, the specifics of what Enzolytics will own post-deal are not detailed in the sources I found. For the most accurate and up-to-date information, I recommend checking Enzolytics’ official announcements or contacting them directly.
This is what I am coming up with on who filed , this is what came back as the answer below , but for now we have not been told exactly what Enzolytics holds or doesn't . So for now none of us know what exactly Enzolytics actually will retain from this deal. We are all hoping CC carries thru on the original plan of licensing. The below states the same thing the doctor is saying , so is he speaking as Enzolytics or as the company he heads. Keep in mind all the claims were put out 2 years ago under Enzolytics not the subs that is why we invested in this. Nothing is ever clear.
Yes, Enzolytics has filed for patents in their name. The company has proprietary technology for producing fully human Monoclonal Antibodies (mAbs) against infectious diseases1. They have pending international patent applications covering the use of any of its discovered numerous conserved Coronavirus epitopes or conserved HIV epitopes in the production of monoclonal antibodies, the production of vaccines or use in diagnostic tests for detecting the viruses in patients2.
Enzolytics has also filed a comprehensive U.S. and foreign Patent Cooperation Treaty (PCT) Patent Application covering its invention of a novel, innovative technology for improved diagnostics3. They have made progress on their ongoing program to produce Monoclonal Antibodies to treat animals by filing a comprehensive patent application covering its identification of conserved neutralizable epitopes on the Feline Leukemia (FeLV) virus4.
The company’s intellectual property includes issued U.S. Patents covering its technology relating to a peptide that has been demonstrated in clinical trials to provide anti-HIV-1 retroviral benefit in vivo1. They also have pending patent applications covering their anti-HIV monoclonal antibody technology1.
In addition, they have pending patent applications covering the proprietary methodology for producing fully human neutralizing monoclonal antibodies against infectious diseases, including Rabies, influenza A, influenza B, Tetanus, Diphtheria, HIV-2, Anthrax, Smallpox, H1N1 influenza, Herpes Zoster, Varicella Zoster and Ebola1.
Please note that while I strive to provide the most accurate and up-to-date information, it’s always a good idea to check the latest updates from official sources or trusted news outlets.
Learn more
1
enzolytics.com
2
marketscreener.com
3
digitaljournal.com
4
finance.yahoo.com
5
bing.com
6
finance.yahoo.com
7
nasdaq.com
8
ca.finance.yahoo.com
9
seekingalpha.com
did Biogenysis file for patents in their name of the following listed as the company The Company has proprietary technology for producing fully human Monoclonal Antibodies (mAbs) against infectious diseases which is currently being employed to produce Monoclonal Antibody therapeutics for treating the CoronaVirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company has also identified conserved epitopes on and has plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). The Company has also analyzed epitopes of animal viruses and plans to produce mAbs for treating these animal viruses.god
So now if you switch out Enzolytics to Biogenysis this is what you get as an answer
Yes, Biogenysis has filed for patents. The company has proprietary technology for producing fully human Monoclonal Antibodies (mAbs) against infectious diseases123. The pending applications contain 23 separate patent claims covering the 19 discovered highly conserved antigens and epitopes (sites) on the SARS CoV-2 virus123. These include antibodies that bind to the disclosed antigens and epitopes, vaccines based on the antigens, methods of treating, preventing, or reducing the risks of SARS CoV-2 infection with the antigens or binding proteins, and methods and kits for detecting or diagnosing infection by SARS CoV-2 using the antigens or binding proteins123.
Through computer analysis (Artificial Intelligence (AI)), the company discovered 19 immutable conserved virus sites on the COVID-19 virus by analyzing 2.8 million SARS CoV-2 isolates23. These sites are now claimed as patentable based on their novel specificity and the finding that they are conserved on SARS-CoV-223. This is significant because antibodies produced to bind to these conserved, immutable sites can neutralize the virus without the possibility of “virus escape” due to virus mutation23.
However, I couldn’t find specific information about patents related to HIV-1, Feline Leukemia virus, HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). For the most accurate and up-to-date information, I recommend checking the official patent databases or contacting Biogenysis directly.
Learn more
1
benzinga.com
2
finance.yahoo.com
3
accesswire.com
4
bio
Here is what was filed , at the bottom of your link you can download and this is what opens , what is funny when reading thru they make reference to the shareholders of Enzolytics but none of the common man has been issued shares.
I would still like to know how SAGA had roughly a small share structure and held a share price of 10+ with nothing to show for it, now a share structure of 45m+ more and hold a 11+ share price with very little cash on hand and still nothing to show for it. Please explain how that is possible someone please take a shot at that . Owning a .025 company doesn't work something that is real to support the 11+ share price using their own filings or lack of .
https://storage.courtlistener.com/recap/gov.uscourts.ded.84075/gov.uscourts.ded.84075.25.0.pdf
https://storage.courtlistener.com/recap/gov.uscourts.ded.84075/gov.uscourts.ded.84075.29.0.pdf
https://storage.courtlistener.com/recap/gov.uscourts.ded.84075/gov.uscourts.ded.84075.29.1.pdf
https://storage.courtlistener.com/recap/gov.uscourts.ded.84075/gov.uscourts.ded.84075.29.2.pdf
https://storage.courtlistener.com/recap/gov.uscourts.ded.84075/gov.uscourts.ded.84075.30.0.pdf
Hey any of the ( X ), discord, or anyother platform ask Chandra what he is naming his yacht? GLTA
Under the terms of the agreement, Biogenysis, Inc. (“BGEN”) and Virogentics Inc. (“VIRO”) will become wholly owned subsidiaries of Sagaliam Acquisition Corp, which is currently trading on NASDAQ1. The new company will adopt the name SAGA Scientific Holdings Corp.1.
1 accesswire.com
https://markets.financialcontent.com/stocks/article/accwirecq-2023-4-17-enzolytics-inc-announces-execution-of-non-binding-term-sheet-with-the-special-purpose-acquisition-company-sagaliam-acquisition-corp-and-updates-the-progress-on-the-african-project
The other thing that is on a timeline for SAGA, which they have not addressed shown below , along with the plan to the SEC. If the judge rules against them and the creation of the 45m shares they will be delisted. Oh what will December hold for all of us? GLTA
Sagaliam Acquisition Corp received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC on May 26, 2023. The letter notified the company that for the last 30 consecutive business days prior to the date of the letter, the company’s Market Value of Listed Securities was below the $50 million minimum requirement for continued listing on the Nasdaq Global Market1.
In accordance with Nasdaq Listing Rule 5810 © (3) ©, the company will have 180 calendar days, or until November 22, 2023, to regain compliance with the MVLS Rule1. If the company does not regain compliance by this date, it will receive written notification that its securities are subject to delisting1.
Learn more
1
finance.yahoo.com
2
investing.com
3
globenewswire.com
4
nasdaq.com
5
mornings
The big misinformation is the share structure hasnt changed since the big run up. Listen at the 55 second to 1:12 That is when I stopped listening. GLTA
Everything that you have been asking people here that don't have an answer for you, better than writting thoses letters you tell everyone to write. Do you need gas money I am sure we can scrape it up for you. 30 miles really GLTA
BM that would be better then sending all types of letters. I know if I lived 30 miles away I would drive over and ask questions and verify they are there and will be for awhile. You are close enough tocheckout the investment for all of us.
Have a great Thanksgiving GLTA
Thanks for the updates and email address so it can be lit up by all that would like to do so. GLTA
Maybe that A S S Clown will move it up to .10 for all of us. GLTA
I think they are doing that so they can give the other 400+ to make whole later on to us and we will be grateful GLTA